Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
6
3
1
0
Axcella Health Inc.
Share · US05454B2043 · AXLA (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Axcella Health Inc.
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float -
Shares Float -
Shares Outstanding 2,73 M
Company Profile for Axcella Health Inc. Share
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Company Data
Name Axcella Health Inc.
Company Axcella Health Inc.
Symbol AXLA
Website
https://www.axcellahealth.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US05454B2043
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Craig R. Jalbert CIRA
Market Capitalization 13 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 840 Memorial Drive, 02139 Cambridge
IPO Date 2019-05-09
Stock Splits
| Date | Split |
|---|---|
| 19.09.2023 | 1:25 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | AXLA |
More Shares
Investors who hold Axcella Health Inc. also have the following shares in their portfolio:
